Literature DB >> 19166382

Gene therapy in type 1 diabetes.

Jessamyn Bagley1, Jesus Paez-Cortez, Chaorui Tian, John Iacomini.   

Abstract

Type 1 diabetes (T1D) is caused by the autoimmune-mediated destruction of insulin-producing beta cells in the pancreas. T1D affects as many as 3 million patients in the United States alone, with 15,000 new cases developing every year (Juvenile Diabetes Research Foundation), and presently there is no cure for T1D. In recent years, there has been a great deal of interest in developing gene therapy approaches to treat T1D. Gene therapy approaches tend to fall into three broad categoriesthose aimed at preventing or curing autoimmunity, those aimed at restoring insulin production through islet transplant or genetically engineered insulin production, and approaches that aim to prevent the morbidity and mortality associated with this complex disease. We review these studies here.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19166382     DOI: 10.1615/critrevimmunol.v28.i4.30

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  2 in total

Review 1.  Minireview: beta-cell replacement therapy for diabetes in the 21st century: manipulation of cell fate by directed differentiation.

Authors:  Vijay Yechoor; Lawrence Chan
Journal:  Mol Endocrinol       Date:  2010-03-10

2.  Molecular chimerism in IgE-mediated allergy: B-and T-cell tolerance toward highly immunogenic exogenous antigens.

Authors:  Ulrike Baranyi; Rudolf Valenta; Thomas Wekerle
Journal:  Chimerism       Date:  2013 Jan-Mar
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.